Skip to main content

Table 1 Quality assessment of all included studies

From: Gefitinib provides similar effectiveness and improved safety than erlotinib for east Asian populations with advanced non–small cell lung cancer: a meta-analysis

Study Selection Comparability Exposure Randomization Masking Accountability of all patients Quality (score)
Randomized controlled trial
 2012 Kim [26]     4
 2016 Urata [10]     5
 2017 Yang [11]     5
Retrospective study
 2010 Kim [19]     7
 2010 Hotta [20]     9
 2010 Hong [21]     7
 2011 Wu [22]     9
 2011 Shin [12]     7
 2011 Togashi [23]     8
 2011 Fan [14]     8
 2011 Jung [24]     6
 2012 Wu [25]     8
 2012 Suzumura [27]     8
 2013 Yoshida [28]     8
 2013 Shao [29]     9
 2013 Lee [30]     8
 2013 Yu [31]     8
 2014 Lim [32]     9
 2014 Sato [13]     8
 2014 Lin [33]     7
 2014 Ren [34]     8
 2014 Li [35]     8
 2014 Takeda [36]     6
 2015 Otsuka [37]     9
 2015 Song [38]     7
 2015 Koo [39]     7
 2016 Ruan [40]     8
 2016 Hirano [41]     8
 2016 Suh [42]     7
 2016 Kashima [43]     8
 2017 Kuan [15]     8